@dr_yakupergun Avatar @dr_yakupergun Yakup Ergün

Yakup Ergün posts on X about in the, ai, this is, how to the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [-----] #

Followers Line Chart

CreatorRank: [-------] #

CreatorRank Line Chart

Social Influence

Social category influence currencies 2% countries 1% cryptocurrencies 1% travel destinations 1%

Social topic influence in the 7%, ai 5%, this is 2%, how to 2%, stage 2%, if you 2%, the first 2%, status 2%, list 2%, pts 2%

Top accounts mentioned or mentioned by @oncbrothers @suyogcancer @onder_haka2124 @medwatchkate @larvol @ptarantinomd @mayocancercare @gicancerdoc @erikahamilton9 @renohemonc @dryakupergun @niusanford @anistoumeh @abisivamd @doctoromene @phsiao4 @k_yadavir @drkatepedersen @usfda @mayohemeonc

Top assets mentioned Frontline Ltd. (FRO)

Top Social Posts

Top posts by engagements in the last [--] hours

"🤔 The https://t.co/4YqaXSMFBA record looks concerning for this paper hopefully the authors and journal can explain The https://t.co/4YqaXSMFBA record looks concerning for this paper hopefully the authors and journal can explain"
X Link 2026-02-06T18:30Z [----] followers, [----] engagements

"Neoadjuvant ET + CDK4/6is in BC Despite a small sample size and methodological limits: In HR+/HER2 neoadjuvant disease lack of radiologic response after [--] NACT cycles supports an early switch to NET + CDK4/6 improving response from 32% to 62%. https://academic.oup.com/oncolo/article/doi/10.1093/oncolo/oyag032/8466438 https://academic.oup.com/oncolo/article/doi/10.1093/oncolo/oyag032/8466438"
X Link 2026-02-07T19:48Z [----] followers, [----] engagements

"Unethical Authorship Practices in Scientific Publications Gift authorship in scientific publishing refers to listing an individual as an author despite the absence of a meaningful intellectual contribution to the study. It typically involves senior figuressuch as department heads or supervisorsadded out of courtesy hierarchy or the belief that their name will increase the chances of publication. This practice is unethical because it misrepresents contribution dilutes accountability and undermines the credibility of authorship itself. Authorship is not a reward a favor or a strategic tool; it"
X Link 2026-02-09T09:26Z [----] followers, [----] engagements

"HER2+ mMBC in asymptomatic patients proactive cranial screening: Symptomatic brain metastases: 0% vs 9.5% Brain metastases detected smaller and with better performance score Reduced need for WBRT https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-3557/774233/Proactive-brain-screening-using-contrast-enhanced https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-3557/774233/Proactive-brain-screening-using-contrast-enhanced"
X Link 2026-02-09T18:04Z [----] followers, [----] engagements

"Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis treatment and follow-up https://www.annalsofoncology.org/article/S0923-7534%2826%2900042-6/fulltext https://www.annalsofoncology.org/article/S0923-7534%2826%2900042-6/fulltext"
X Link 2026-02-10T11:28Z [----] followers, [----] engagements

"Neoadjuvant TCHP vs THP in HER2-positive breast cancer This is an ongoing analysis but here are the early ITT pCR results. [--] studies included (2 prospective randomized [--] retrospective). Total patients: [----] pCR rates (ITT): TCHP➡62.3% THP➡61.7% Pooled OR: [----] (95% CI 0.821.60) I = 68% Bottom line: adding carboplatin to taxane + dual HER2 blockade does not meaningfully improve pCR. Multiple confounders remain (treatment adherence completion rates.). Analyses are ongoing these are preliminary results. Subgroup analysis.🔍 https://twitter.com/i/web/status/2021203845943079362"
X Link 2026-02-10T12:45Z [----] followers, [----] engagements

"Cumulative cancer risk by sex across [--] countries: Up to age 50: In all countries risk is 1.52.5 higher in women than in men. Up to age 75: In all countries except Kenya lifetime risk is higher in men. https://academic.oup.com/jnci/article/118/2/370/8471732 https://academic.oup.com/jnci/article/118/2/370/8471732"
X Link 2026-02-11T14:29Z [----] followers, [----] engagements

"Great summaries on stage I-III colorectal cancer👇 Come to the next Mayo Clinic Heme/Onc Practice Update and Board Review next year. You could see @DrKatePedersen knock it out of the park with a stellar review of localized colorectal cancer Everything you need to know (and more) on how to manage patients. @MayoCancerCare https://t.co/z1A8s1z0bG Come to the next Mayo Clinic Heme/Onc Practice Update and Board Review next year. You could see @DrKatePedersen knock it out of the park with a stellar review of localized colorectal cancer Everything you need to know (and more) on how to manage"
X Link 2026-02-12T18:33Z [----] followers, [----] engagements

"Tumor Treating Fields (TTFields) have been approved by the FDA for pancreatic cancer👇 TTFields (+chemo) now @US_FDA ✅ for locally advanced pancreatic ductal adenocarcinoma based off #PANOVA3: - mOS [----] vs. 14.2mos (HR: 0.82) - AEs: 76% device related skin side effects - Is this going to be rapidly adopted in practice #gism #OncTwitter #MedTwitter #pancsm https://t.co/WJbzh7aPhL TTFields (+chemo) now @US_FDA ✅ for locally advanced pancreatic ductal adenocarcinoma based off #PANOVA3: - mOS [----] vs. 14.2mos (HR: 0.82) - AEs: 76% device related skin side effects - Is this going to be rapidly"
X Link 2026-02-14T15:35Z [----] followers, [----] engagements

"HERA trial: In premenopausal HR+/HER2+ eBC adding OFS to adjuvant ET significantly improves DFS and OS vs TAM alone (10-yr DFS 70.9% vs 59.6; OS 84.7% vs 74.0). AI + OFS is associated with superior DFS and a favorable OS trend versus TAM + OFS https://jnccn.org/view/journals/jnccn/23/12/article-p539.xml https://jnccn.org/view/journals/jnccn/23/12/article-p539.xml"
X Link 2026-01-31T21:14Z [----] followers, [----] engagements

"In a phase III randomized trial in metastatic NSCLC administering immunotherapy in the early hours significantly prolonged PFS and OS. This study makes one thing clear: in NSCLC when you give immunotherapy matters as much as what you give https://www.nature.com/articles/s41591-025-04181-w https://www.nature.com/articles/s41591-025-04181-w"
X Link 2026-02-03T04:27Z [----] followers, 21.7K engagements

"Immunotherapy has finally been approved in ovarian cancer. A 4-month OS difference in platinum-resistant disease is quite good. Of course there are many questions. While atezolizumab failed why was pembrolizumab effective Can the immunomodulatory effect of weekly paclitaxel alone explain this PD-1 vs PD-L1 diff In the population with high FR expression and PD-L1 1% (overlap) should the choice be mirvetuximab or chemo plus pembrolizumab There are many questions but the increase in available options is encouraging. https://twitter.com/i/web/status/2021339251170783469"
X Link 2026-02-10T21:43Z [----] followers, [---] engagements

"The patient I struggle most with when making treatment decisions is one with stage III disease and a germline BRCA2 mutation. For maintenance therapy should I choose a PARP inhibitor a CDK4/6 inhibitor or consider sequential use Are CDK4/6 inhibitors effective in gBRCA2-mutant (RB1 loss) patients"
X Link 2026-02-13T15:33Z [----] followers, [---] engagements

"In the PLANet study low-dose pembrolizumab was evaluated but another key difference was the absence of carboplatin. Although the pCR rate was higher in the pembrolizumab arm pCR rates in both arms were approximately 10% lower than those observed in KEYNOTE-522 (including the control arm). This difference is most likely attributable to the omission of carboplatin. Therefore in my view carboplatin should be included in the neoadjuvant regimen for patients without tolerance issues. https://twitter.com/i/web/status/2023087573988696492 https://twitter.com/i/web/status/2023087573988696492"
X Link 2026-02-15T17:30Z [----] followers, [--] engagements

"What Systemic HT Black Box Removal Means for BC Survivors Menopausal HT is not an absolute contraindication solely because of a history of BC; however it is not a benign treatment that can be prescribed indiscriminately. The decision should be individualized based on tumor biology time since diagnosis and symptom burden. https://jamanetwork.com/journals/jama/fullarticle/2844755utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=020726"
X Link 2026-02-07T07:56Z [----] followers, [---] engagements

"Health headlines from just the last month: Mexican scientists have completely eradicated HPV. Turkish scientist has eliminated brain tumors. Spanish scientists have completely cured pancreatic cancer. Korean scientists have completely cured colon cancer. At first we tried to correct these stories when they were rolled out with misleading headlines. But at this point the situation has clearly spiraled out of control. Even the scientists behind these studies openly state that the headlines are wrong and that the actual findings are far more limited and nuanced. Still the same exaggerated claims"
X Link 2026-02-08T10:00Z [----] followers, [----] engagements

"Nivolumab plus chemotherapy as first-line treatment for advanced gastric gastroesophageal junction and esophageal adenocarcinoma: 5-year follow-up results from CheckMate [---] 5y OS➡16% vs 6% (PD-L1 5%) https://www.annalsofoncology.org/article/S0923-7534%2826%2900059-1/fulltext https://www.annalsofoncology.org/article/S0923-7534%2826%2900059-1/fulltext"
X Link 2026-02-11T20:25Z [----] followers, [---] engagements

""If you torture your data long enough they will tell you whatever you want to hear" @SuyogCancer 😊"
X Link 2026-02-12T06:45Z [----] followers, [----] engagements

"Retrospective analysis of [---] RET fusionpositive lung adenocarcinoma cases Most common fusion: KIF5B-RET With selective RET inhibitors nonKIF5B-RET showed longer PFS No PFS difference between first-line chemo-IO and RET inhibitors (both [--] mos) https://www.lungcancerjournal.info/article/S0169-5002%2826%2900058-9/fulltext https://www.lungcancerjournal.info/article/S0169-5002%2826%2900058-9/fulltext"
X Link 2026-02-12T18:06Z [----] followers, [---] engagements

"This distinction is important: In HER2-positive mCRC if a RAS mutation is present T-DXd should be preferred. If RAS is wild-type either T-DXd or other anti-HER2 agents can be used. Excellent summaries👇 Want more reasons to join the Mayo Clinic Heme/Onc Practice Update and Board Review. You get to see @GIcancerDoc speak and see my fav therapy algorithm on mCRC. Join us next year in Honolulu @MayoCancerCare @MayoHemeOnc https://t.co/jeKeN2hLOx Want more reasons to join the Mayo Clinic Heme/Onc Practice Update and Board Review. You get to see @GIcancerDoc speak and see my fav therapy algorithm"
X Link 2026-02-12T18:39Z [----] followers, [----] engagements

"RT @OncBrothers: This is the algorithm weve used during our discussion with @elmayermd on HR+ early stage #BreastCancer #OncTwitter #Med"
X Link 2026-02-13T14:44Z [----] followers, [--] engagements

"In my opinion it is a waste of resources. I hope that robust clinical evidence will put an end to the speculation and hope-mongering in this area. Ivermectin a macrocyclic lactone discovered in the mid-1970s plays a critical role in the treatment of a wide range of parasitic diseases in humans as well as in veterinary practice. Over the past decade researchers have explored repurposing this molecule as an anticancer Ivermectin a macrocyclic lactone discovered in the mid-1970s plays a critical role in the treatment of a wide range of parasitic diseases in humans as well as in veterinary"
X Link 2026-02-14T11:38Z [----] followers, [----] engagements

"Algorithm of ET targeted treatment options after ET + CDK4/6 inhibitors. Some options are not yet approved caution From Dr. Alessandra Gennaris excellent discussion at #ESMO25👇"
X Link 2026-02-16T10:05Z [----] followers, [----] engagements

"TIGITs immuno-oncology teachings "To date [--] companies have tested [--] anti-TIGIT candidates across [---] clinical trials enrolling [-----] patients(). The estimated cost of these trials ranges between [---] and [---] billion USD" A complete disaster👇 https://www.nature.com/articles/d41573-026-00031-7 https://www.nature.com/articles/d41573-026-00031-7"
X Link 2026-02-16T20:09Z [----] followers, [---] engagements

"Low-carbohydrate / ketogenic diets: Are we sure theyre safe to recommend in cancer Glucose restriction boosts tumor-derived exosomal TRAIL suppressing lung macrophages and NK cells and creating an immunosuppressed niche that facilitates lung metastasis. https://www.cell.com/cell/abstract/S0092-8674(25)00728-7_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867425007287%3Fshowall%3Dtrue https://www.cell.com/cell/abstract/S0092-8674(25)00728-7_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867425007287%3Fshowall%3Dtrue"
X Link 2025-11-21T07:37Z [----] followers, [----] engagements

"As repeatedly shown high TMB after targeted therapy in MSS mCRC is not immunogenic. Its just the pooled signal of tiny low-dose mutational islands from multiple metastatic sites not a true uniform TMB rise in the tumors themselves. The biology stays cold; ICB doesnt work https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-2566/767301/Acquired-High-Tumor-Mutational-Burden-and-Activity https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-2566/767301/Acquired-High-Tumor-Mutational-Burden-and-Activity"
X Link 2025-11-21T12:55Z [----] followers, [----] engagements

"Case discussion: 55-year-old postmenopausal pT2N1 G2 ER/PR-positive HER2 Ki-67 30% Oncotype RS [--]. According to RxPONDER there is no indication for chemotherapy. Would you recommend adjuvant CDK4/6 inhibitor Yes No Yes No"
X Link 2025-11-23T17:50Z [----] followers, 13.6K engagements

"@Jad_Sattar I wont be able to attend San Antonio but I will definitely read your poster. Thank you"
X Link 2025-11-25T20:03Z [----] followers, [--] engagements

"Given the toxicity and financial burden of systemic therapies I dont really trust the PFS curves which tend to converge over time. I avoid toxic regimens until an option showing solid OS benefit becomes available and I rely on local treatments. Choosing among local therapies however is utter chaos 🙄"
X Link 2025-11-27T09:32Z [----] followers, [----] engagements

"In ROS1-positive disease early progression is often driven by solvent-front mutations such as G2032R. The prolonged PFS signal here suggests that these clones may not emerge as early as expected or that lorlatinib is suppressing them more effectively in the frontline setting. If resistance evolves this late sequencing becomes more strategic: starting with lorlatinib and switching to repotrectinib or taletrectinib once a solvent-front mutation appears is a biologically sound approach"
X Link 2025-11-28T10:16Z [----] followers, [---] engagements

"SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025) https://link.springer.com/article/10.1007/s12094-025-04139-x https://link.springer.com/article/10.1007/s12094-025-04139-x"
X Link 2025-11-29T18:44Z [----] followers, [----] engagements

"The third trial to demonstrate an overall survival benefitafter KEYNOTE-671 (perioperative pembrolizumab) and CheckMate [---] (neoadjuvant nivolumab)is RATIONALE-315 evaluating perioperative tislelizumab https://www.annalsofoncology.org/article/S0923-7534(25)06287-8/fulltext https://www.annalsofoncology.org/article/S0923-7534(25)06287-8/fulltext"
X Link 2025-12-02T11:29Z [----] followers, [----] engagements

"ctDNAs prognostic value has already been well established. What this study adds is the first clear signal that ctDNA may also be predictive for adjuvant celecoxib benefit. ✅In the ctDNA+ subgroup adding celecoxib led to a relative risk reduction of roughly 40% in both DFS and OS https://jamanetwork.com/journals/jamaoncology/fullarticle/2842596 https://jamanetwork.com/journals/jamaoncology/fullarticle/2842596"
X Link 2025-12-04T17:27Z [----] followers, [----] engagements

"#SABCS25 After nearly a decade of therapeutic stagnation in the first-line treatment of HER2-positive breast cancer since the publication of CLEOPATRA we suddenly find ourselves facing a cascade of paradigm-shifting developments. The PATINA trial DESTINY-Breast09 and now the eagerly awaited HER2CLIMB-05 study to be presented at SABCS25. We already know the study will be positive; what remains is the granular data. Still three consecutive positive trials inevitably create clinical friction: who should receive which regimen and for how long For HR+/HER2+ disease the emerging landscape now"
X Link 2025-12-07T12:42Z [----] followers, [----] engagements

"The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup https://www.nature.com/articles/s41581-025-01031-3 https://www.nature.com/articles/s41581-025-01031-3"
X Link 2025-12-08T16:52Z [----] followers, 10.2K engagements

"#SABCS25 The question of which adjuvant ET is most effective in HR+/HER2+ eBC has been a persistent gray zone. According to the exploratory analysis of the ALTTO (BIG 2-06) trial AIs provide superior DFS compared with tamoxifen regardless of age menopausal status grade or T/N stage"
X Link 2025-12-09T06:57Z [----] followers, [----] engagements

"This slide perfectly illustrates the paradox of modern HR+ metastatic breast cancer management. On paper the postCDK4/6 landscape is elegant and biologically rational: NGS-guided decisions ESR1-targeted oral SERDs PI3K/AKT pathway inhibitors PARP inhibitors and even CDK4/6 continuation strategies. Almost every resistance mechanism has a proposed solution. In real life howeverin many countries including my ownmost of these red-highlighted options are simply not accessible. The algorithm exists the evidence exists the biomarkers exist but the treatments do not. So the question is unavoidable:"
X Link 2025-12-13T09:59Z [----] followers, 21.3K engagements

"Prostate cancer https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02221-4/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02221-4/fulltext"
X Link 2025-12-18T18:38Z [----] followers, 17.4K engagements

"T-DXd: Mechanism of Action Visualized A few years ago we were actively looking for professional illustrators to create figures like these. Now a single-line prompt is often enough to generate high-fidelity scientifically accurate visuals💥"
X Link 2025-12-19T12:59Z [----] followers, [----] engagements

"@Larvol I was working on the top meme cancer studies of 2025😊 This list turned out greatthank you. By the way the number of views they received is truly surprising. DB-09 was viewed nearly [--] million times 😯"
X Link 2025-12-23T18:19Z [----] followers, [---] engagements

"2025 is coming to a close and one thing is clear: It has been an exceptionally intense year in breast cancer. Clinical trials that have the potential to change practice and defined the year 👇 #bcsm ✨🎄"
X Link 2025-12-24T12:49Z [----] followers, [----] engagements

"In the era of IO it is worth re-evaluating the extent of LND Excessive removal of non-metastatic LNs reduces IO efficacy in recurrent BTC 💬We should revise our surgical practices in line with the mechanisms of action of modern therapies not only BTC https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-25-3296/771244/Excessive-dissection-of-non-metastatic-tumorredirectedFrom=fulltext https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-25-3296/771244/Excessive-dissection-of-non-metastatic-tumorredirectedFrom=fulltext"
X Link 2025-12-30T12:11Z [----] followers, [----] engagements

"Sacituzumab Tirumotecan in EGFR-TKIResistant EGFR-Mutated Advanced NSCLC https://www.nejm.org/doi/full/10.1056/NEJMoa2512071 https://www.nejm.org/doi/full/10.1056/NEJMoa2512071"
X Link 2026-01-01T01:34Z [----] followers, [----] engagements

"Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC (FLAURA2) https://www.nejm.org/doi/full/10.1056/NEJMoa2510308query=TOC&cid=DM2433073_NEJM_Non_Subscriber&bid=-1002224504 https://www.nejm.org/doi/full/10.1056/NEJMoa2510308query=TOC&cid=DM2433073_NEJM_Non_Subscriber&bid=-1002224504"
X Link 2026-01-01T01:35Z [----] followers, [----] engagements

"In metastatic BC concomitant use of T-DXd and radiotherapy (10 days) did not increase G3 toxicity and showed no adverse impact on PFS/OS in a multicentre RW cohort of [---] patients. One case of symptomatic radionecrosis was reported after brain RT https://www.thebreastonline.com/article/S0960-9776(26)00001-9/fulltext https://www.thebreastonline.com/article/S0960-9776(26)00001-9/fulltext"
X Link 2026-01-03T06:15Z [----] followers, [----] engagements

"2025 FDA approvals 🔹35% of FDA approvals in [----] (16/46) were oncology drugs exceeding the 5-year average of 29%. 🔹Oncology remains the dominant therapeutic area. 🔹ICIs ADCs bispecifics and targeted kinase inhibitors stood out. https://www.nature.com/articles/d41573-026-00001-z https://www.nature.com/articles/d41573-026-00001-z"
X Link 2026-01-03T15:06Z [----] followers, [----] engagements

"Because most of these patients receive neoadjuvant therapy platinum agents are usually utilized in that setting and therefore are not carried over into the adjuvant phase. However in high-risk TNBC patients who undergo upfront surgery for any reasonparticularly those who are younger have a high Ki-67 level are germline BRCA mutation carriers and are expected to tolerate treatmentI would consider adding a platinum agent. It is important not to compromise taxane delivery by having to discontinue therapy due to platinum-related toxicity. It should also be kept in mind that the BR003 trial"
X Link 2026-01-04T16:24Z [----] followers, [----] engagements

"Lung cancer in women: current evidence and future research priorities 📌Lung cancer differs by sex: women have more EGFR/HER2 and more never-smokers. Screening benefit is higher but criteria miss women. Sex-aware care needed. https://www.lungcancerjournal.info/article/S0169-5002%2825%2900797-4/fulltext https://www.lungcancerjournal.info/article/S0169-5002%2825%2900797-4/fulltext https://www.lungcancerjournal.info/article/S0169-5002%2825%2900797-4/fulltext https://www.lungcancerjournal.info/article/S0169-5002%2825%2900797-4/fulltext"
X Link 2026-01-05T08:39Z [----] followers, [----] engagements

"In HER2-positive breast cancer achieving nearly [--] years of PFS was once unimaginable. I do not know when it will happen but one day we will place breast cancer among diseases that are completely treatablecurable rather than merely controllable [--] studies that we touched on during Her2+ #BreastCancer highlights 🗣 from #SABCS25 with @DrHBurstein ✅ #DESTINYBreast11 ✅ #DESTINYBreast05 ✅ #Her2Climb05 ✅ #PATINA #OncTiwtter #bcsm #MedTwitter https://t.co/ob71J603ki [--] studies that we touched on during Her2+ #BreastCancer highlights 🗣 from #SABCS25 with @DrHBurstein ✅ #DESTINYBreast11 ✅"
X Link 2026-01-06T17:25Z [----] followers, [----] engagements

"@SuyogCancer Only [--] months of PFS with atezolizumab I hope we will receive a satisfactory explanation during the presentation"
X Link 2026-01-07T06:00Z [----] followers, [---] engagements

"Why did atezolizumab monotherapy (antiPD-L1) result in a much shorter PFS than pembrolizumab and nivolumab monotherapy (antiPD-1) mPFS👇 COMMIT Atezo : [---] mo KN-177 Pembro: [----] mo CM-8HW Nivo(central MSI): [----] mo (local MSI): [----] mo COMMIT (NRG-GI004 / SWOG-S1610) 1L dMMR/MSI-H mCRC interim data with key limitations from #ASCOGI2026 Design: Phase III heavily amended; final comparison atezo vs mFOLFOX6 + bev + atezo N analyzed: [---] (40/arm) small numbers Analysis: Interim (65% information https://t.co/58Mq86plYB COMMIT (NRG-GI004 / SWOG-S1610) 1L dMMR/MSI-H mCRC interim data with key"
X Link 2026-01-07T07:54Z [----] followers, [----] engagements

"Case discussion 43-year-old premenopausal woman with synchronous colon and breast cancer. Colon: right-sided T3N1 MSI-H. Breast: right mastectomy + SLNB. Two foci: node negative [---] cm luminal Alike [---] cm grade [--] Ki-67 40% Oncotype DX: score [--] gPALB2 mutation present How would you design the adjuvant treatment strategy for this patient @OncBrothers @SuyogCancer @PTarantinoMD @Dr_RShatsky @BijoyTelivala @ErikaHamilton9 @stolaney1 @RenoHemonc @UmutDisel @BianchiniGP @JAMouabbi @kazuki_nozawa @Onco_Cifu88 @benjiwal"
X Link 2026-01-09T18:22Z [----] followers, [----] engagements

"SCOT [----] Final OS analysis 🔎In [----] pts with stage II (high-risk) and stage III CRC long-term follow-up (10 years) shows no OS difference between [--] vs [--] months of adjuvant oxaliplatin-fluoropyrimidine. 5-yr OS: 82.4% vs 82.4% (HR 0.96) 💡Outcomes were regimen-dependent: CAPOX: [--] months was non-inferior to [--] months FOLFOX: non-inferiority was not statistically confirmed Risk-based analysis in stage III: Low-risk (T3N1): similar OS with [--] vs [--] months High-risk (T4 and/or N2): small absolute OS differences 📌Rectal cancer (unique to SCOT within IDEA): [--] months achieved OS comparable to 6"
X Link 2026-01-10T08:17Z [----] followers, 12.1K engagements

"Schematic representation of MSI testing based on ESMO and ASCO recommendations Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer https://t.co/atNieB5VrF https://t.co/kvCDGoLGX3 Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer https://t.co/atNieB5VrF https://t.co/kvCDGoLGX3"
X Link 2026-01-11T16:45Z [----] followers, 10.4K engagements

"Academic Oncology at a Crossroads: Rebuilding a Sustainable Career Path Academic oncology is in its death throes "The solution isnt superficial wellness programs or pizza parties: it requires structural change"👇 https://jnccn.org/view/journals/jnccn/24/1/article-e257139.xmlcontent=fullHtml-7602 https://jnccn.org/view/journals/jnccn/24/1/article-e257139.xmlcontent=fullHtml-7602"
X Link 2026-01-12T15:15Z [----] followers, [----] engagements

"Clinical pathway for newly recurrent or de novo HR-positive/HER2-negative MBC👇 Personalizing therapies over the course of hormone receptorpositive/HER2negative metastatic breast cancer - Singareeka Raghavendra Great review👇 https://t.co/VKRmEvYeZ3 https://t.co/p3qlbW4W8S Personalizing therapies over the course of hormone receptorpositive/HER2negative metastatic breast cancer - Singareeka Raghavendra Great review👇 https://t.co/VKRmEvYeZ3 https://t.co/p3qlbW4W8S"
X Link 2026-01-13T10:53Z [----] followers, [----] engagements

"Because the mPFS in the chemo + trastuzumab arms are essentially identical it is clear that the trials were conducted in very similar patient populations. Since the zanidatamab + tislelizumab arm is superior both numerically and in terms of hazard ratios (compared with KN-811) it is likely to become the new SoC. However as @Erman_Akkus pointed out the fact that the control arm was not pembro + trast + chemo once again highlights the classic ethical problem in clinical trials"
X Link 2026-01-13T13:16Z [----] followers, [---] engagements

"In asymptomatic EGFR-mutant NSCLC with brain metastases adding upfront SRS to osimertinib provides numerically better intracranial PFS and OS but in the 79-patient STARLET analysis this difference is not statistically significant. https://www.jto.org/article/S1556-0864(26)00001-8/abstract https://www.jto.org/article/S1556-0864(26)00001-8/abstract"
X Link 2026-01-14T17:14Z [----] followers, [----] engagements

"Premenopausal HR+/HER2+ eBC Adjuvant ET RD after NAT OFS + AI pCR after NAT risk-adapted Stage III OFS + AI Stage III TAM OFS Upfront surgery baseline stage-driven ET Principle: RD = ER-dependent chemo-resistant needs ET intensification Great editorial👇 https://www.thebreastonline.com/article/S0960-9776(26)00006-8/fulltext https://www.thebreastonline.com/article/S0960-9776(26)00006-8/fulltext"
X Link 2026-01-15T09:01Z [----] followers, [--] engagements

"FROST study: In selected older patients with early-stage ER+ / HER2 T1 node-negative breast cancer can cryoablation replace surgery 6-year results: IBTR 3.6% no serious toxicity 💡 Appears to be a reasonable alternative to surgery https://link.springer.com/article/10.1245/s10434-025-18991-2 https://link.springer.com/article/10.1245/s10434-025-18991-2"
X Link 2026-01-16T17:39Z [----] followers, [----] engagements

"@ValenzaCarmine @Harvard @HarvardChanSPH @harvardmed @IEOufficiale @LaStatale @DFCI_BreastOnc @DanaFarber Congratulations. I have a question: Are there survival outcome data for patients who receive [--] years of AI + LHRH and then switch to tamoxifen monotherapy versus those who continue AI + LHRH"
X Link 2026-01-16T17:57Z [----] followers, [---] engagements

"What is complete resection in lung cancer👇 From Dr Paul Van Schil ESMO Advanced Course on Early-Stage NSCLC 2025"
X Link 2026-01-21T10:29Z [----] followers, [----] engagements

"High peak-dose corticosteroids used for irAE management in stage IV NSCLC are associated with worse OS and cancer-specific survival while cumulative steroid dose and second-line immunosuppressants do not impact outcomes. https://www.esmoopen.com/article/S2059-7029(25)01922-2/fulltext https://www.esmoopen.com/article/S2059-7029(25)01922-2/fulltext"
X Link 2026-01-21T19:03Z [----] followers, [----] engagements

"Can we truly label a study with Grade [--] toxicity as 'acceptable' or 'manageable' My letter on the necessity of "redefining toxicity terminology in clinical trial reporting" (original title)👇 @OncoAlert https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01045-6/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01045-6/fulltext"
X Link 2024-07-26T08:17Z [----] followers, 69.3K engagements

"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: EMBER-3 📌Imlunestrant prolonged PFS in patients with ESR1 mutations 📌Imlunestrant-abemaciclib improved PFS regardless of ESR1 mutation status https://www.nejm.org/doi/full/10.1056/NEJMoa2410858 https://www.nejm.org/doi/full/10.1056/NEJMoa2410858"
X Link 2025-03-26T21:09Z [----] followers, [----] engagements

"D3S-001 in advanced solid tumors with KRASG12C mutations: a phase [--] trial G12Ci-naive ORR NSCLC➡67% CRC➡89% Pancreatic➡75% G12Ci-pretreated ORR NSCLC➡30% No G4 or [--] TRAE 💥The new generation KRAS inhibitors seem quite effective https://www.nature.com/articles/s41591-025-03688-6 https://www.nature.com/articles/s41591-025-03688-6 https://www.nature.com/articles/s41591-025-03688-6 https://www.nature.com/articles/s41591-025-03688-6 https://www.nature.com/articles/s41591-025-03688-6 https://www.nature.com/articles/s41591-025-03688-6"
X Link 2025-04-29T13:09Z [----] followers, 15.9K engagements

"#ESMOBreast25 is in [--] Days One of the key upcoming presentations: EMBER-3 Subgroup Analysis 📌Imlunestrant + abema improved PFS after CDK4/6i (vs. Imlu) 📌No abema benefit after abema 📌Efficacy observed after palbo and ribo 💥Consistent benefit in ESR1+ and PI3K-mutant pts https://twitter.com/i/web/status/1920365896981225770 https://twitter.com/i/web/status/1920365896981225770"
X Link 2025-05-08T06:31Z [----] followers, 14.1K engagements

"#ESMOBreast25 EMBER-3: Imlu+Abema vs Imlu in CDK4/6i-pretreated ER+ HER2- ABC pts mPFS➡9.1 vs [---] mo (HR: 0.51) Prior CDK4/6i: Palbociclib (n:176)➡HR [----] Ribociclib (76)➡HR [----] Abemaciclib (23)➡HR [----] Visceral mets: HR [----] ESR1m: HR [----] #ESMOAmbassadors @myESMO https://twitter.com/i/web/status/1922663708876017784 https://twitter.com/i/web/status/1922663708876017784"
X Link 2025-05-14T14:42Z [----] followers, 16.4K engagements

"@ASCO Educational Book New Drugs New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies An absolutely outstanding review👇 https://ascopubs.org/doi/10.1200/EDBK-25-473384 https://ascopubs.org/doi/10.1200/EDBK-25-473384"
X Link 2025-07-10T11:18Z [----] followers, [----] engagements

"The article refers to the EMBER-4 study but the study being discussed actually appears to be EMBER-3. If any of the authors or editors see this post I would recommend that they verify it"
X Link 2025-07-10T12:51Z [----] followers, [---] engagements

"@PTarantinoMD Considering that in January [----] the FDA approved Dato-DXd despite not meeting the co-primary endpoint of OS I do not think it will pay much attention to the secondary () endpoint of OS in the EMBER-3 trial"
X Link 2025-09-25T20:08Z [----] followers, [---] engagements

"Primary vs Metastasis: Genomic Differences In the analysis of [----] matched primarymetastatic samples from [----] patients in the AACR Project GENIE database: 🔹Metastatic tumors show a modest increase in mutation burden 🔹FGA is higher reflecting metastatic genomic instability 🔹Eleven genes are more frequent in metastases (MYC CDKN2A ESR1 AR etc.) 🔹The most pronounced differences appear in lung breast colorectal pancreatic and prostate cancers. 💬The study shows that metastatic tumors exhibit a limited but biologically interpretable degree of genomic divergence compared with primary tumors"
X Link 2025-12-08T09:40Z [----] followers, 10.1K engagements

"@Larvol @SABCSSanAntonio ER is set to take center stage today with updated EMBER-3 and evERA data being presented"
X Link 2025-12-12T14:56Z [----] followers, [---] engagements

"Case discussion Gastric ca 43F gastric adeno ca cT4N+M0 Staging lap: no peritoneal dz PD-L1 CPS [--] MSS diffuse type Neoadj: 4c FLOT + 2c durva (MATTERHORN) Surg: Gastrectomy + D2 LND R0. Path: pT4aN1 poor response What would you recommend for adjuvan treatment FLOT + Durvalumab FLOT Observation Change chemo backbone FLOT + Durvalumab FLOT Observation Change chemo backbone"
X Link 2026-01-26T19:41Z [----] followers, [----] engagements

"Izalontamab brengitecan (Iza-bren; BL-B01D1) a first-in-class EGFR-HER3 bispecific antibodydrug conjugate for patients with EGFR-mutated NSCLC: Pooled analysis of phase [--] and phase [--] trials https://www.annalsofoncology.org/article/S0923-7534%2826%2900018-9/fulltext https://www.annalsofoncology.org/article/S0923-7534%2826%2900018-9/fulltext"
X Link 2026-01-27T17:34Z [----] followers, [----] engagements

"In this BC cell line study cross-resistance to sequential ADCs is driven more by shared payload mechanisms than by target loss 💬Much about ADCs remains unknown but as preclinical and clinical data accumulate more rational strategies against distinct resistance pathways will emerge https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-25-3321/771997/Payload-Diversification-Overcomes-Resistance-and https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-25-3321/771997/Payload-Diversification-Overcomes-Resistance-and"
X Link 2026-01-27T19:12Z [----] followers, [----] engagements

"Thank you to all colleagues who voted and shared their comments. A large majority agrees on completing adjuvant treatment. However it is clear that more rational biology-driven strategies need to be developed for patients with poor response. We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by Dr. Yakup Ergn (@dr_yakupergun): https://t.co/9QKuzBeiNU This time AI and clinicians largely agreed. Across models https://t.co/LbvBsGerOB We asked leading AI models to simulate oncologist poll"
X Link 2026-01-28T09:59Z [----] followers, [----] engagements

"ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer Update➡Maintenance rucaparib in the first-line setting and mirvetuximab soravtansine for subsequent platinum-ineligible patients. https://www.esmoopen.com/article/S2059-7029%2825%2901902-7/fulltext https://www.esmoopen.com/article/S2059-7029%2825%2901902-7/fulltext"
X Link 2026-01-28T10:02Z [----] followers, [----] engagements

"Case discussion NSCLC 58M unresectable stage III lung adenocarcinoma EGFR exon [--] L861Q mt + PD-L1 CPS 5% Tx: Definitive concurrent chemoradiotherapy completed. What would be your post-CRT approach Osimertinib Durvalumab Surveillance Osimertinib Durvalumab Surveillance"
X Link 2026-01-28T18:44Z [----] followers, [----] engagements

"Olaparib showed a high ORR (75%) in [--] pts with gPALB2 mutations. In [--] pts with somatic BRCA1/2 mutations a 36.7% ORR was observed reflecting clinically meaningful and in some cases durable activity although the prespecified statistical efficacy threshold was not met (50%) https://ascopubs.org/doi/10.1200/JCO-25-02075 https://ascopubs.org/doi/10.1200/JCO-25-02075"
X Link 2026-01-28T21:36Z [----] followers, [----] engagements

"Great new BUT Lately headlines claiming that pancreatic cancer has been completely eliminated in mice are circulating widely. The core information is true; the conclusion drawn from it is wrong. Mariano Barbacid and his team demonstrated a triple-targeted treatment combination that very strongly suppresses pancreatic cancer in mouse models. In some mice tumors completely disappeared and no recurrence was observed. But lets pause. This is a preclinical study. Meaning: It has not been tested in humans Efficacy and safety are unknown It does not represent a clinical treatment Seeing complete"
X Link 2026-01-29T06:22Z [----] followers, 162.9K engagements

"Im truly sorry for your fathers passing pancreatic cancer is indeed a devastating disease. Youre absolutely right: accurate communication is crucial. This preclinical work by Mariano Barbacids team is a meaningful scientific signal and offers new hope but translation to patients remains the big challenge. Grateful for highlighting both the promise and the necessary caution. https://twitter.com/i/web/status/2016888805198897225 https://twitter.com/i/web/status/2016888805198897225"
X Link 2026-01-29T14:58Z [----] followers, [----] engagements

"We know that ER-low tumors predominantly exhibit basal-like features. In both KEYNOTE-756 and CheckMate-7FL neoadjuvant immunotherapy showed a meaningful increase in pCR specifically in the ER-low subgroup. For this patient I would definitely give neoadjuvant therapy. If accessible I would add immunotherapy. In the adjuvant setting I would still give endocrine therapy. Based on the germline test results such as BRCA and PALB2 an adjuvant PARP inhibitor may also come into consideration"
X Link 2026-01-29T18:41Z [----] followers, [---] engagements

"Emerging landscape of KRAS inhibitors in cancer treatment https://www.cell.com/cancer-cell/fulltext/S1535-6108%2826%2900010-3 https://www.cell.com/cancer-cell/fulltext/S1535-6108%2826%2900010-3"
X Link 2026-01-30T04:58Z [----] followers, [----] engagements

"Hallmarks of cancer2026 Cancer is not driven by isolated cellular traits but by an evolving biological system that operates through its interactions with the surrounding environment and therefore can only be effectively targeted in combination👇 https://www.cell.com/cell/fulltext/S0092-8674%2825%2901498-9 https://www.cell.com/cell/fulltext/S0092-8674%2825%2901498-9"
X Link 2026-01-30T11:29Z [----] followers, [----] engagements

"Having just digested the PATINA and DB-05 data I still think it is too early to extrapolate these results to the adjuvant setting 🙂 but it is clear that this will be a major topic of discussion going forward. In early-stage disease I have concerns that overtreatment may drive the emergence of highly resistant clones; therefore until more robust data are available my current preference would be T-DXd + ET --ET https://twitter.com/i/web/status/2017223051864088645 https://twitter.com/i/web/status/2017223051864088645"
X Link 2026-01-30T13:07Z [----] followers, [--] engagements

"Sensational headlines sell hope Many cancer treatments work in mice. But the vast majority fail in humans. If results seen in mice translated directly to humans cancer would have ended decades ago Thats why precision and responsibility in scientific communication matter https://twitter.com/i/web/status/2017492863810961760 https://twitter.com/i/web/status/2017492863810961760"
X Link 2026-01-31T06:59Z [----] followers, 13.6K engagements

"I would like to thank all my colleagues who voted and shared their valuable comments. A clear majority favored osimertinib after CRT in this case. The main challenge in this case was not the common EGFR mutations but how to approach uncommon EGFR mutations. These patients were not included in the LAURA trial and PACIFIC does not provide mutation-specific data for this subgroup. However in the metastatic setting we know that several uncommon but sensitizing EGFR mutations respond quite well to osimertinib as shown in UNICORN. Based on this indirect evidence osimertinib could be considered"
X Link 2026-02-01T08:11Z [----] followers, [----] engagements

"In unresectable stage III non-sqNSCLC treated with cCRT followed by Durva KRAS mutationsparticularly when accompanied by STK11 and/or CDKN2A co-alterationsare associated with shorter PFS and an increased risk of distant especially brain metastases. https://www.jto.org/article/S1556-0864%2826%2900018-3/fulltext https://www.jto.org/article/S1556-0864%2826%2900018-3/fulltext"
X Link 2026-02-01T12:59Z [----] followers, [----] engagements

"The phase II ATTENTION trial showed that first-line aumolertinib plus apatinib significantly prolonged PFS (HR 0.41) compared with aumolertinib alone in EGFR-mutant aNSCLC. The WJOG9717L phase II RCT failed to show a PFS benefit from adding bevacizumab to osimertinib in the first-line setting https://www.nature.com/articles/s41392-025-02550-y https://www.nature.com/articles/s41392-025-02550-y"
X Link 2026-02-02T06:20Z [----] followers, [----] engagements

"There is a lot we can learn from patients It reminds us of the hardestand the most importantpart of being a physician: EMPATHY the part we should never forget Lets truly listen to our patients meet their eyes be fully present and hear what words alone cant say Big C👇"
X Link 2026-02-02T12:16Z [----] followers, [----] engagements

"Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer Great review👇 https://www.nature.com/articles/s41571-026-01120-7 https://www.nature.com/articles/s41571-026-01120-7"
X Link 2026-02-03T12:01Z [----] followers, [----] engagements

"Randomization was done at baseline. From that moment on every variable that emergesincluding treatment durationis part of the treatment effect. In other words treatment duration is not a cause but a consequence. And this consequence has already been tested. PFS itself explains why OS cannot be attributed to cumulative treatment exposure. The PFS curves separate at the first assessment showing that the effect starts immediately. If OS were driven simply by longer drug exposure such an early separation would not be seen. Moreover timing was strictly controlled during the first four cycles. This"
X Link 2026-02-03T17:26Z [----] followers, [----] engagements

"Therapy for Stage IV NonSmall Cell Lung Cancer With Driver Alterations: ASCO Living Guideline https://ascopubs.org/doi/10.1200/JCO-25-02822 https://ascopubs.org/doi/10.1200/JCO-25-02822 https://ascopubs.org/doi/10.1200/JCO-25-02822 https://ascopubs.org/doi/10.1200/JCO-25-02822"
X Link 2026-02-03T21:18Z [----] followers, [----] engagements

"Therapy for Stage IV NonSmall Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline https://ascopubs.org/doi/10.1200/JCO-25-02825 https://ascopubs.org/doi/10.1200/JCO-25-02825 https://ascopubs.org/doi/10.1200/JCO-25-02825 https://ascopubs.org/doi/10.1200/JCO-25-02825"
X Link 2026-02-03T21:20Z [----] followers, [----] engagements

"#WorldCancerDay Close the Care Gap 🌍🌎🌏 Same Cancer➡Same Care ⚖"
X Link 2026-02-04T08:13Z [----] followers, [---] engagements

"Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review Great review👇 https://www.cancertreatmentreviews.com/article/S0305-7372(26)00011-3/fulltext https://www.cancertreatmentreviews.com/article/S0305-7372(26)00011-3/fulltext"
X Link 2026-02-04T19:46Z [----] followers, [----] engagements

"DESTINY-Breast09: Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2508668 https://www.nejm.org/doi/full/10.1056/NEJMoa2508668"
X Link 2026-02-05T04:18Z [----] followers, [----] engagements

"@SuyogCancer @NEJM @NiuSanford @Alfdoc2 @drsarahsam @PTarantinoMD If you torture your data long enough they will tell you whatever you want to hear👍"
X Link 2026-02-05T14:24Z [----] followers, [---] engagements

"My Top [--] Breast Cancer Abstracts list at #ESMO24 👇"
X Link 2024-08-27T13:53Z [----] followers, 21.2K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing